Allogene Therapeutics, Inc.
Financial highlights
| Metric | FY 12/31/25 | FY 12/31/24 | FY 12/31/23 | FY 09/30/23 | FY 06/30/23 |
|---|---|---|---|---|---|
| Income Statement | |||||
| Revenue | $0.0 | $<0.1 | $0.1 | — | — |
| Operating income | -$209.3 | -$273.2 | -$327.7 | — | — |
| Net income | -$190.9 | -$257.6 | -$327.3 | — | — |
| Cash Flow Statement | |||||
| Free cash flow | -$149.6 | -$201.0 | -$239.2 | — | — |
Shares outstanding 345.2M · Free float 83.9%
Annual filing data through FY ended December 31, 2025; float as of July 15, 2026.